A deficient expression of LARGE1 was detected in colon adenocarcinoma (by ‒ 1.30-fold), prostate cancer (by ‒ 1.61-fold), infiltrating urinary-bladder cancer (by ‒ 1.85-fold), breast carcinoma (by ‒ 1.20-fold), glioma (by ‒ 2.63-fold) and melanoma (by ‒ 1.45-fold) [106], as well as in renal cell carcinoma (clear cells) (by ‒ 1.72 or ‒ 1.45-fold) [76, 106], rhabdomyosarcoma [96] and non-small-cell lung cancer [125]. Here, LARGE1 is linked to prostate cancer.